TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Benefit Provided by Sessions of Sophrology on the Per Operative Management of Parkinsonian Patients Planned for a Deep Brain Stimulation Surgery.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patient (age greater than or equal to 18 years)~* Patient with idiopathic Parkinson's disease with programmed deep brain stimulation (VIM target, NST, single or bilateral GPI);~* Planned intervention in an awake patient (implying MOCA\> 21 (Montreal Cognitive Assessment));~* Patient understanding the course of the study;~* Patient who has given informed consent in writing;~* Patient benefiting from a system of social insurance.~Exclusion Criteria:~* - Intervention under general anesthesia;~* Pregnant or nursing women;~* Major person under protective measures (safeguard of justice, curatorship and guardianship);~* Person deprived of liberty.~* Patient having already had a practice in yoga, sophrology, hypnotherapy superior or equal to 5 sessions

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients without sessions of sophrology (Type: NO_INTERVENTION): The control group is also composed of Parkinsonian patients waiting for deep brain surgery but will not have any special preparation for the procedure. They will be subjected to the same assessments at the same time as the sophrology group.
- Patients with sessions of sophrology (Type: EXPERIMENTAL): The experimental group is composed of patients with Parkinson's waiting for deep brain surgery. They will benefit from 10 sessions of sophrology in preparation for the intervention 5 weeks before this one.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Admission to the ICU with severe pneumonia (IDSA/ATS 2016/2019): presence of signs, symptoms and confirmatory chest imaging consistent with pneumonia (e.g. fever, cough and pulmonary infiltrate by chest radiograph)~* Age ≥18 years~* Positive respiratory culture (with or without an initial positive rapid identification test and/or Gram stain) for Gram-negative bacteria including, but not limited to, P. aeruginosa, K. pneumoniae, E. coli, S. marcescens, H. influenzae, Enterobacter spp., M. catarrhalis, A. baumannii, Achromobacter spp., P. mirabilis, and/or B. cepacia~* Received within the last 72 hours or will receive meropenem, cefepime, or piperacillin/tazobactam therapy~Exclusion Criteria:~* Pregnancy~* Prisoners~* Allergy to the beta-lactams to be administered in this study~* On renal replacement therapy at the time of randomization~* Baseline culture resistant to the beta-lactams in the study~* COVID patients enrolled in other trials

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Continuous Antibiotic Dose Over 24 hours Arm (Type: ACTIVE_COMPARATOR): Subjects will be receiving a continuous dose of antibiotic prescribed by their doctor for the duration they choose.
- Intermittent Antibiotic Dose Over 30 minutes (Type: ACTIVE_COMPARATOR): Subjects will be receiving an intermittent dose of antibiotic prescribed by their doctor for the duration they choose.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Metabolic and Cardiovascular Effects of Renal Denervation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Essential hypertension~* Systolic blood pressure \>160 mm Hg despite ≥3 antihypertensive drugs~* Clinical patients accepted for renal denervation~Exclusion Criteria:~* Type 1 diabetes~* Pregnancy~* Glomerular filtration rate ≤45 ml/min/1,73 m2~* Pacemaker/ICD~* Myocardial infarction/stroke the last 12 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Single arm (Type: EXPERIMENTAL): 15 clinical patients undergoing renal denervation

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Rollover Study for Continuing NBI-98854 Administration in Pediatric Subjects With Tourette Syndrome

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Have a clinical diagnosis of Tourette Syndrome (TS)~2. Have participated in the NBI-98854-TS2004 or NBI 98854-TS2005 Phase 2 studies~3. If using maintenance medication(s) for TS and/or TS spectrum diagnoses (e.g. obsessive-compulsive disorder \[OCD\], Attention-Deficit Hyperactivity Disorder \[ADHD\]), be on stable doses~4. Be in good general health~5. Subjects of childbearing potential who do not practice total abstinence must agree to use hormonal or two forms of nonhormonal contraception (dual contraception) consistently during the screening, treatment and follow-up periods of the study~Exclusion Criteria:~1. Have an active, clinically significant unstable medical condition within 1 month before screening~2. Have a known history of long QT syndrome or cardiac arrhythmia~3. Have a known history of neuroleptic malignant syndrome~4. Have a cancer diagnosis within 3 years prior to screening (some exceptions allowed)~5. Have an allergy, hypersensitivity, or intolerance to VMAT2 inhibitors~6. Have a blood loss ≥250 mL or donated blood within 56 days, or donated plasma within 7 days, before the start of the study~7. Have a known history of substance dependence, substance (drug) or alcohol abuse within 3 months before the start of the study~8. Have a significant risk of suicidal or violent behavior~9. Have received an investigational drug within 30 days before the start of the study or plan to use an investigational drug (other than NBI-98854) during the study~10. Are currently participating in another NBI-98854 clinical study~11. Are pregnant (for females)

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- NBI-98854 (Type: EXPERIMENTAL): NBI-98854 administered once daily for up to 96 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Changes in Echogenicity and Muscle Stiffness in Elastography After Botulinum Toxin Injection a Spastic Muscle

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* A first stroke older than nine months (acute phase and subacute stroke).~* Hemiplegia cerebral vascular following this stroke.~* Hemiplegia with an overall motor deficit plegic lower limb muscle testing level less than or equal to 3 and associating a localized spasticity lower plegic member, on the plantar flexors, assessed by the upper Ashworth Scale or equal to 1 with an injection of botulinum toxin indication of the sural triceps.~* written consent.~Exclusion Criteria:~* Old stroke with motor impairment of the lower limb in the chronic stage.~* Concomitant muscle disease (eg myopathy, myositis ...).~* Patients who already received a botulinum toxin injection into the gastrocnemius muscles.~* Subjects with defibrillator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- patients with hemiplegia after stroke (Type: EXPERIMENTAL): ultrasound echogenicity paraclinical assessment and elastography to patients with hemiplegia following stroke with an indication of injection of botulinum toxin into the triceps sural

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients ≥ 18 years of age.~* Ankylosing spondylitis as defined by the modified New York criteria for ≥ 3 months prior to baseline.~* Active disease at screening and baseline (Bath Ankylosing Spondylitis Disease Activity Index \[BASDAI\] ≥ 4.0, spinal pain visual analog scale \[VAS\] ≥ 40).~* Inadequate response or intolerant to 1 or more previous non-steroidal anti-inflammatory drugs (NSAIDs).~* Inadequate response to treatment with etanercept, infliximab, adalimumab, or golimumab because of inadequate efficacy.~* Tumor necrosis factor (TNF) antagonist therapy must have been discontinued at least 8 weeks prior to baseline (etanercept 4 weeks).~* Traditional disease-modifying anti-rheumatic drugs (DMARDs) must be withdrawn for at least 4 weeks prior to baseline (methotrexate, sulfasalazine, and hydroxychloroquine or chloroquine may be allowed if at stable dose for at least 4 weeks prior to baseline).~* Oral corticosteroids (≥ 10 mg/day prednisone or equivalent) and NSAIDs/cyclooxygenase-2 \[COX-2\] inhibitors must be at stable dose for at least 4 weeks prior to baseline.~Exclusion Criteria:~* Major surgery (including joint surgery) within 8 weeks prior to screening or planned major surgery within 6 months after randomization.~* Total ankylosis of spine (as determined by investigator).~* Inflammatory rheumatic disease other than ankylosing spondylitis.~* Active, acute uveitis at baseline.~* Previous treatment with tocilizumab.~* Intra-articular or tendon injections or parenteral corticosteroids within 4 weeks prior to screening.~* History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.~* Active current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infection.~* History of or currently active primary or secondary immunodeficiency.~* Body weight \> 150 kg.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tocilizumab 4 mg/kg (Type: EXPERIMENTAL): Patients received tocilizumab 4 mg/kg intravenously every 4 weeks for 24 weeks.
- Tocilizumab 8 mg/kg (Type: EXPERIMENTAL): Patients received tocilizumab 8 mg/kg intravenously every 4 weeks for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Patients received placebo to tocilizumab intravenously every 4 weeks for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Antineoplastons A10 and AS2-1 In Patients With Carcinoma of the Bladder

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed stage IV bladder carcinoma that is unlikely to respond to existing therapy and for which no curative therapy exists or stage IV newly diagnosed, incurable bladder carcinoma~* Measurable disease by CT scan~* Tumor must be greater than 2 cm at the largest diameter for the lymph nodes located in the head, neck, axillary, inguinal, or femoral areas and at least 0.5 cm in the largest diameter for other localizations~* 18 and over~* Karnofsky 60-100%~* Life expectancy: greater than 2 months~* WBC at least 2,000/mm\^3~* Platelet count at least 50,000/mm\^3~* Bilirubin no greater than 2.5 mg/dL~* SGOT/SGPT no greater than 5 times upper limit of normal~* No hepatic failure~* Creatinine no greater than 2.5 mg/dL~* No history of renal conditions that contraindicate high dosages of sodium~* No severe heart disease~* No uncontrolled hypertension~* No history of congestive heart failure~* No history of other cardiovascular conditions that contraindicate high dosages of sodium~* No severe lung disease~* Not pregnant or nursing~* Fertile patients must use effective contraception during and for 4 weeks after study participation~* No serious active infections or fever~* No other serious concurrent disease~* At least 4 weeks since prior immunotherapy and recovered~* No concurrent immunomodulating agents~* At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas) and recovered~* Concurrent corticosteroids allowed~* At least 8 weeks since prior radiotherapy and recovered~* Recovered from any prior operative procedure~* Prior cytodifferentiating agent allowed~Exclusion Criteria:~- Prior antineoplaston therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Antineoplastons (Type: EXPERIMENTAL): Antineoplaston therapy (Atengenal + Astugenal) by IV infusion every four hours for at least 12 months. Study subjects receive increasing dosages of Atengenal and Astugenal until the maximum tolerated dose is reached.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Cranberry Capsules on Urinary Infection Rates in Spinal Cord Injured Patients During Post Acute Rehabilitation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Previously essentially healthy~2. Newly acquired spinal cord injury, T12 level or higher~3. Receiving in-patient care on the rehabilitation ward.~4. Expected admission duration \>= 4 weeks~5. 16 years old or older~Exclusion Criteria:~1. Current or previous disorder that increases the risk of urinary tract infection including diabetes, urological disorder, previous operation on urinary tracts or kidneys, immune dysfunction~2. Severe head injury with impairment of cognitive function~3. Allergy to cranberry~4. Renal failure~5. Warfarin (Coumarin) treatment with unstable INR~6. Current symptomatic urinary tract infection

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cranberry capsule (Type: EXPERIMENTAL): None
- Placebo capsule (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Visual Outcomes After Vivity Toric IOL Implantation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Calculated lens power within study IOL range of 15.0 diopters to 25.0 diopters and toric range of T3 to T6~* Willing and able to comprehend informed consent form and to complete 1 day and 3-4 month postoperative visit~* Potential postoperative best corrected distance visual acuity of 20/20 or better in each eye based on medical opinion of investigator~Exclusion Criteria:~* Ocular pathology or comorbidity that could reduce potential postoperative best corrected distance visual acuity~* Ocular trauma or zonular weakness/instability~* Diagnosis of glaucoma or high-risk glaucoma suspect~* Previous refractive surgery~* Unreliable preoperative biometry measurements~* Severe dry eye or ocular surface disease

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Vivity Toric IOL (Type: OTHER): Patients with cataract that had phacoemulsification and Vivity Toric IOL implantation.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hemodynamic Effects of Blood Flow Variation in Continuous Renal Replacement Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-89~* Acute renal failure or end-stage renal disease necessitating CRRT~* Admitted to the MICU service~* If on vasopressor/inotropic agent, norepinephrine as only intravenous pressor~* If on vasopressor/inotropic agent, at stable pressor dose for at least four hours~* If on IV fluids, stable dose of crystalloids \<= 100cc/hour and is not receiving colloids for 4 hours or more prior to initiation of CRRT~* Mean arterial pressure (MAP) \>= 65~* Arterial catheter present for continuous blood pressure monitoring~* CRRT duration of 48 hours or less using NxStage System One dialysis system~* successfully tolerated CRRT for at least 4 hours without clotting or hemodynamic instability~* no other procedures, blood products transfusion, or additional medication administration are anticipated during the study period~Exclusion Criteria:~* listed for organ transplant~* atrial fibrillation, other irregular heart rhythm, unstable arrhythmia~* need for more than one intravenous vasopressor agent~* intravenous vasopressor/inotropic agent other than norepinephrine (ie dobutamine, dopamine, vasopressin, epinephrine)~* therapeutic anticoagulation being administered~* known acute myocardial infarction as defined by elevated troponin along with a documented clinical diagnosis during current hospitalization~* known acute stroke, intracerebral hemorrhage, intracranial mass effect, or elevated intracranial pressure within the last 30 days.~* dialysis catheter malfunction and unable to maintain target blood flow rate~* fluid removal (ultrafiltration) rate \> 100mL/hour

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- Experimental arm (Type: EXPERIMENTAL): The patients will have the blood flow rate adjusted on CRRT gradually increased to assess the effect on hemodynamics

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Smartphone App to Improve Functional Outcomes in Ankle Sprains

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~(i) Age 12-21 years (ii) Presenting to the Emergency Department of the Children's Hospital, London Health Sciences Centre, London, Ontario, with a unilateral acute (\<48 hours) ankle inversion injury.~(iii) Use a WiFi enabled smartphone with either an iOS or Android operating system with enough memory capability to host the App.~The diagnosis of an ankle inversion injury will be made on a clinical basis by the treating emergency physician after a fracture has been ruled out radiographically. We will include all grades of ankle injuries, including suspected Salter-Harris I of the distal tibia or fibula.~Exclusion Criteria:~* Children unable to read or understand English above at least a grade 8 literacy level~* Children who are not independently ambulatory (without the use of an assistive device)~* Children with a developmental disability precluding the full comprehension of study-related procedures,~* Children with multi-system or multi-limb injuries~* Children with a concomitant lower extremity fracture or dislocation (with the exception of a suspected Salter-Harris type I injury).

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 21 Years
- Healthy Volunteers: f

Study Arms:
- Smartphone app (Type: EXPERIMENTAL): The smartphone group will not be given paper-based discharge instructions in the ED. They will download onto their smartphone device an Intervention App that will allow recording of the above mentioned study outcomes and contains an interactive educational component encompassing the identical information outlined in the paper handout. The app will provide educational guidance towards recovery using a feedback algorithm that will recommend on a daily basis, the use of ice, elevation, range of motion exercises, and/or analgesics based on the participant's report of their pain using the FPS-R.
- Paper handout (Type: ACTIVE_COMPARATOR): The paper handout group will be asked to read the paper-based discharge instructions in the ED, outlining pharmacological and non-pharmacological pain management and return to activity. They will download onto their smartphone device a Recording App that will only allow them to record the following study outcome measures: daily use of ice, analgesia, range of motion exercises, elevation, pain using the Faces Pain Scale - Revised (FPS-R), and ASKp scores on days 3, 5, 7, 10, 12, and 14.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy